
Cover image: Brad Rodu speaks at a harm reduction event in Manila, Philippines, in November 2026. (Photo: 2Firsts)
Key Points
30 Years of Research: Rodu said continued opposition to lower-risk tobacco alternatives remains his biggest surprise. He considers declining cigarette smoking progress even if nicotine use increases.
Nicotine and Cancer: Rodu argued that nicotine itself does not cause cancer in humans. Separate research reviewed by 2Firsts identified increased risks for certain cancers among snus users.
Sweden's Experience: Rodu highlighted historical differences in smoking, snus use and lung cancer mortality between Swedish men and women.
Youth Vaping: Rodu urged nicotine pouch manufacturers to prevent underage use, while arguing that responsibility also extends to parents and young people.
FDA and WHO: Rodu welcomed recent FDA decisions but criticized slow reviews and inadequate risk communication. He expressed little optimism about a near-term change in WHO's stance.
2Firsts
Nov. 20, 2026
Philip Morris International (PMI) held its Technovation Manila event in the Philippines on November 10, drawing approximately 550 attendees for discussions on tobacco harm reduction, scientific research and smoke-free innovation.
In an exclusive interview with 2Firsts on the sidelines of the event, Brad Rodu, professor emeritus at the University of Louisville School of Medicine, said declining cigarette smoking represented public-health progress even if the use of other nicotine products increased.
Trained in oral pathology and with a background in cancer research, Rodu held an endowed chair in tobacco harm reduction research at the University of Louisville from 2005 to 2025. He has studied tobacco harm reduction for more than three decades, focusing on the health implications of replacing cigarettes with smokeless alternatives and contributing to scientific and policy discussions in the field.
During the interview, Rodu discussed nicotine and cancer, Sweden's experience with snus, youth vaping in the United States, recent regulatory decisions by the U.S. Food and Drug Administration (FDA), and the future of tobacco harm reduction.
Reflecting on his research career since the 1990s, Rodu said he was surprised by continued opposition to alternatives he considered substantially less harmful than cigarettes.
"What surprises me most is the opposition to a much safer form of using tobacco," he said.
Declining Smoking, Nicotine and Cancer Risks
Asked how public-health progress should be measured if cigarette smoking declines while the use of other nicotine products increases, Rodu questioned whether continued nicotine use among adults should necessarily be viewed as a problem.
"I don't see a problem with uptake of safer nicotine products if smoking goes to near zero," he said.
Rodu argued that the major diseases associated with cigarette smoking were not directly caused by nicotine itself. He compared nicotine with caffeine, saying the two substances had similarities in their effects, although they were not identical.
He said the main historical difference lay in how the two substances were consumed: caffeine through drinks and nicotine predominantly through burning tobacco and inhaling smoke.
According to the FDA, cigarette smoke contains more than 7,000 chemicals, including over 70 that can cause cancer.
"But nicotine itself is not dangerous. It's addictive," Rodu said.
Rodu said smokers who were already dependent on nicotine should move to less harmful delivery systems rather than continue inhaling cigarette smoke.
Asked about differing scientific views on nicotine and cancer, Rodu referred to epidemiological studies of Swedish men who used snus, a form of oral smokeless tobacco.
He said those studies had not shown higher cancer rates among snus users than among non-users. He also questioned whether findings from laboratory experiments involving cells could be directly applied to humans.
"Nicotine itself does not cause cancer in humans. We don't have any evidence for that," he said.
Following the interview, Rodu told 2Firsts by email that he was not aware of epidemiological studies specifically examining nicotine itself and cancer. He provided reviews of smokeless tobacco and cancer, including a 2009 systematic review by Peter Lee and Jan Hamling.
Separately, 2Firsts reviewed a 2023 systematic review published in the International Journal of Cancer. It reported evidence of increased risks for certain cancers among exclusive Swedish snus users, with the certainty of the findings varying from moderate to very low. The review assessed snus use, not nicotine exposure in isolation.

Sweden's Snus Experience and Lung Cancer Trends
Rodu said his interest in Sweden developed while reviewing historical lung cancer mortality statistics from the World Health Organization (WHO).
He described lung cancer as a "sentinel disease" of smoking, explaining that mortality trends could provide insights into a population's historical smoking patterns.
Reviewing statistics dating back to 1950, he noticed that Swedish men had comparatively low lung cancer mortality rates.
Rodu believed the pattern was related to lower cigarette smoking and the longstanding use of snus among Swedish men.
"I must go to Sweden to understand why," he recalled thinking.
In 2002, Rodu undertook a research sabbatical in Sweden, working with Swedish collaborators to investigate tobacco use and smoking-related diseases.
In a 2009 study co-authored with Philip Cole, which Rodu provided to 2Firsts after the interview, the researchers compared lung cancer mortality across 25 European Union countries using data from around 2002.
The study reported an age-standardized lung cancer mortality rate of 77 deaths per 100,000 among Swedish men aged 45 and older, compared with 166 across the countries studied.
In the same comparison, Swedish women's lung cancer mortality rate was the sixth-highest among the 25 countries studied.
Rodu pointed to historical differences in smoking and snus use between Swedish men and women as an important part of his interpretation. He said Swedish women had traditionally smoked more and used snus less frequently than men, although more women were now using snus and nicotine pouches.
A separate 2013 study by Rodu and colleagues documented low smoking prevalence alongside snus use in two northern Swedish counties.
The 2013 paper disclosed that Rodu's research was supported by unrestricted grants to the University of Louisville from Swedish Match, Reynolds American, Altria and British American Tobacco, as well as by the Kentucky Research Challenge Trust Fund. The authors said the tobacco manufacturers had no role in that study.
Rodu viewed Sweden's experience as evidence of the potential for smokeless tobacco products to help reduce cigarette smoking. The historical population comparisons, however, do not by themselves establish how much of the decline was caused by snus.

Youth Vaping Offers Lessons for Nicotine Pouches
Asked what the nicotine pouch industry should learn from the rise of vaping, Rodu pointed to controversy over adolescent e-cigarette use in the United States.
He said opposition to vaping had been driven largely by concerns about teenage use.
Rodu acknowledged that youth vaping increased sharply in 2018 and 2019 before declining in subsequent years. He believed much of the earlier increase was probably temporary rather than evidence of lasting nicotine dependence.
"It was more experimentation," he said.
Rodu nevertheless emphasized the importance of preventing underage use of tobacco and nicotine products.
He said nicotine pouch manufacturers should seek to prevent substantial uptake among teenagers, as manufacturers of other tobacco products should.
However, he argued that responsibility did not rest exclusively with manufacturers.
"My opinion is that teen use of tobacco is not exclusively an industry issue," he said.
Rodu said parents and teenagers themselves also had responsibilities. While adolescents frequently experimented with behaviors associated with adulthood, he said society should continue working to protect children.
Rodu Sees FDA Progress but Calls for Better Risk Communication
Asked about recent FDA decisions involving nicotine products, Rodu said the agency appeared to be making greater use of scientific evidence when evaluating smoke-free alternatives.
On October 30, the FDA authorized the marketing of 24 VELO nicotine pouch products through its premarket tobacco product application (PMTA) pathway.
Earlier, on June 30, the agency authorized 20 ZYN nicotine pouch products to be marketed with a specific modified-risk claim. Those products had already received authorization for sale in January 2025.
Commenting on the FDA's recent decisions, Rodu described the agency's efforts to use scientific evidence to authorize smoke-free products as positive steps. He made clear, however, that he had no inside information about its decision-making.
He nevertheless criticized the pace of FDA reviews, arguing that smokers needed access to a wider range of alternatives.
Rodu said a limited selection would not satisfy all smokers, whose preferences for different products varied.
He also called on the FDA to improve public education about the relative health risks of tobacco and nicotine products.
Rodu said the agency had not done enough to help Americans and healthcare professionals understand those differences, although he was encouraged by indications that the FDA's Center for Tobacco Products was giving greater attention to public education.
Tobacco Companies, WHO and the Future of Harm Reduction
Asked where major tobacco companies were falling short in their efforts to reduce smoking-related harm, Rodu declined to offer specific recommendations about corporate strategy.
He said his expertise concerned tobacco-related health, disease and mortality rather than business management.
"I couldn't possibly claim to have any experience in managing a tobacco company," he said.
Nevertheless, Rodu viewed tobacco companies' investment in smoke-free products positively.
"I see progress when tobacco companies are interested in smoke-free products," he said.
He suggested that major companies increasingly recognized the long-term decline of cigarette sales and were developing alternatives for smokers.
Turning to the next five years, Rodu identified a potential change in WHO's position on tobacco harm reduction as one of the most significant developments that could occur.
He argued that WHO's stance influenced tobacco policy discussions in many countries, including decisions affecting access to products he considered less harmful than cigarettes.
"I think the biggest thing that could happen would be a change in the WHO's attitude," he said.
Rodu also pointed to the United Kingdom, Japan and Sweden as markets where the adoption of alternative nicotine products had accompanied declines in cigarette sales.
He cited approximately 18 million e-cigarette users in the United States.
A 2026 study published in NEJM Evidence, which Rodu provided to 2Firsts after the interview, estimated that 17.79 million U.S. adults used e-cigarettes every day or on some days in 2024, based on the National Health Interview Survey.
Rodu said he believed such international trends would eventually make it harder for WHO to disregard tobacco harm reduction.
However, he saw little indication that WHO's position would change in the near future and expressed doubt that a meaningful shift would occur soon.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.










